Wirth S, et al. - Researchers conducted this PEG-B-ACTIVE phase 3 study to test the safety and effectiveness of peginterferon (PegIFN) alfa-2a in children with chronic hepatitis B (CHB). For this investigation, they assessed PegIFN alfa-2a treatment in children aged 3 to <18 years with CHB. They found that PegIFN alfa-2a treatment in children in the immune-active phase of CHB was effective and well tolerated and related to higher incidence of hepatitis B surface antigen (HBsAg) clearance than in adults. For children with CHB, this represents an important advance to the treatment options.